Baxter International Inc. is voluntarily recalling four lots of intravenous solutions to the hospital/user level due to the potential for leaking containers and particulate matter. Baxter was made aware of these issues as the result of two complaints for leaking containers and one customer complaint each for three lots due to particulate matter. In each case, the issue was discovered prior to patient administration and there have been no adverse events associated with these incidents reported to Baxter to date according to the company.

Leaking containers were confirmed in 11 units of one lot (P337857) of 0.9% sodium chloride injection, USP, 100mL in Mini-Bag Plus Container, and a subsequent investigation identified the root cause as a mechanical issue that affected one machine during a single shift. The mechanical issue has since been remedied.

A single unit in a separate lot (P328997) of 0.9% sodium chloride injection, USP, 100mL in Mini-Bag Plus Container was found to contain a fragment of cardboard particulate matter. A unit from lot P339135 of metronidazole injection, USP 500mg/100mL was found to contain cloth fiber particulate matter, and a unit from lot P333930 of Clinimix E 5/15 (5% amino acid with electrolytes in 15% dextrose with calcium) was found to contain a small fragment of dried skin particulate matter.

0.9% Sodium chloride injection, USP, is indicated as a source of water and electrolytes and may also be used as diluent for reconstitution of a powdered drug product packaged in a vial with a 20-mm closure. The lots being recalled were distributed to customers and distributors nationwide between February 22, 2015 and December 28, 2015.

Metronidazole injection, USP, is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole injection, USP, therapy. In a mixed aerobic and anaerobic infection, antibiotics appropriate for the treatment of the aerobic infection should be used in addition to metronidazole Injection, USP. Metronidazole injection, USP, has been shown to be effective in Bacteroides fragilis infections resistant to clindamycin, chloramphenicol and penicillin. The lot being recalled was distributed to customers and distributors nationwide between October 9, 2015 and January 18, 2016.

Clinimix E sulfite-free (amino acid with electrolytes in dextrose with calcium) injections are indicated as a caloric component in a parenteral nutrition regimen. The product is used as the protein (nitrogen) source for offsetting nitrogen loss or for treatment of negative nitrogen balance in patients where the alimentary tract cannot or should not be used, gastrointestinal absorption of protein is impaired, or metabolic requirements for protein are substantially increased. The lot being recalled was distributed to customers and distributors nationwide between May 29, 2015 and December 3, 2015.

Source: Baxter and FDA